| Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT06134414) | Wuhan Createrna Science and Technology Co., Ltd | 2025-12-01 |
| Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) (NCT06687174) | Wuhan Createrna Science and Technology Co., Ltd | 2024-12-31 |
| QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension (NCT06716970) | Wuhan Createrna Science and Technology Co., Ltd | 2024-12-30 |
| Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT06933914) | Wuhan Createrna Science and Technology Co., Ltd | 2024-11-30 |
| A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function (NCT07625618) | Wuhan Createrna Science and Technology Co., Ltd | 2024-09-20 |
| Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (NCT06932471) | Wuhan Createrna Science and Technology Co., Ltd | 2024-08-30 |
| Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy (NCT06932744) | Wuhan Createrna Science and Technology Co., Ltd | 2024-08-30 |
| To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects (NCT06543459) | Wuhan Createrna Science and Technology Co., Ltd | 2024-08-10 |
| A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT06050226) | Wuhan Createrna Science and Technology Co., Ltd | 2023-07-06 |
| QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study (NCT06920836) | Wuhan Createrna Science and Technology Co., Ltd | 2023-06-21 |
| A Study of Multiple Ascending Doses MY008211A in Healthy Adults (NCT05828472) | Wuhan Createrna Science and Technology Co., Ltd | 2023-01-10 |
| A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension (NCT07700875) | Wuhan Createrna Science and Technology Co., Ltd | 2022-12-29 |
| Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects (NCT05828485) | Wuhan Createrna Science and Technology Co., Ltd | 2022-09-26 |
| A Study of Single-dose MY008211A in Healthy Adults (NCT05642585) | Wuhan Createrna Science and Technology Co., Ltd | 2022-05-27 |